Spots Global Cancer Trial Database for efficacy
Every month we try and update this database with for efficacy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer | NCT01194453 | Non-small Cell ... Efficacy | cisplatin, dexa... cisplatin, gemc... | 18 Years - 75 Years | Sun Yat-sen University | |
| Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer | NCT00868491 | Head and Neck C... | docetaxel, cisp... radiotherapy cetuximab, cisp... | 18 Years - | Institute of Oncology Ljubljana | |
| Study of Apatinib as an Inhibitor of Tumor Angiogenesis | NCT00633490 | Tumor | apatinib | 18 Years - 70 Years | Fudan University | |
| Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) | NCT00313781 | Prostatic Neopl... | CP-751,871 docetaxel prednisone docetaxel prednisone | 18 Years - | Pfizer | |
| EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study | NCT01902238 | Efficacy Safety Feasibility | EUS-guided etha... | 18 Years - | Asan Medical Center | |
| Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 | NCT06028672 | Gestational Tro... | Toripalimab Actinomycin-D | 18 Years - 60 Years | Peking Union Medical College Hospital | |
| Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas | NCT00047879 | Glioma | PEG-interferon ... Thalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia | NCT00777738 | Waldenstrom Mac... | BORTEZOMIB | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer | NCT00210184 | Gastric Cancer | Irinotecan asso... | 70 Years - 100 Years | Institut Bergonié | |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors | NCT05915481 | Advanced Solid ... Stereotactic Bo... Immune Checkpoi... Safety Efficacy | Cadonilimab Stereotactic bo... | 18 Years - 75 Years | Peking University Third Hospital | |
| Apatinib for Inoperable Advanced Chondrosarcoma | NCT04260113 | Efficacy Toxicity, Drug | Apatinib Mesyla... | - | Peking University People's Hospital | |
| Efficacy Study of Lucentis in the Treatment of Retinoblastoma | NCT01899066 | Retinoblastoma | Lucentis, chemo... chemotherapy | - | Sun Yat-sen University | |
| Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer | NCT02843581 | Metastatic Esop... | Cryosurgery NK immunotherap... | 30 Years - 70 Years | Fuda Cancer Hospital, Guangzhou | |
| A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. | NCT06298058 | Advanced Solid ... | SIBP-A13 formul... | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors. | NCT05203601 | Tumor | SIBP-03 | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma | NCT02908204 | Esophageal Neop... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | ||
| Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer | NCT00591045 | Stomach Neoplas... Gastric Cancer | mFOLFOX | 30 Years - 70 Years | Peking University | |
| Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) | NCT01997229 | Refractory Gene... | Eculizumab Placebo | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer | NCT01194453 | Non-small Cell ... Efficacy | cisplatin, dexa... cisplatin, gemc... | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa | NCT01000740 | Non-small Cell ... | EGFR Mutation T... Ki-67 protein e... | - | AstraZeneca | |
| Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. | NCT04775173 | Kaposiform Hema... | Sirolimus | 1 Day - 14 Years | West China Hospital | |
| Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer | NCT02739659 | Prostate Carcin... | carbon-ion radi... | 20 Years - 85 Years | Shanghai Proton and Heavy Ion Center | |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation | NCT06243354 | Safety Tolerability Efficacy | Test product: H... | 18 Years - | Sichuan Huiyu Pharmaceutical Co., Ltd | |
| Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | NCT02411019 | Cervical Intrae... | GX-188E | 19 Years - 50 Years | Genexine, Inc. | |
| Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma | NCT02342275 | Hemangioma | Propranolol Atenolol | - 24 Weeks | West China Hospital | |
| Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma | NCT03930498 | Recurrent Nasop... | PD-1 blocking a... Chemotherapy IMRT | 18 Years - 65 Years | Sun Yat-sen University | |
| Kanglaite Injection Phase I Study | NCT00031031 | Solid Tumors Re... Neoplasms | Kanglaite Injec... | 18 Years - | KangLaiTe USA | |
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | NCT03575351 | Lymphoma, Non-H... | Standard of Car... JCAR017 | 18 Years - 75 Years | Celgene | |
| Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | NCT03764553 | Esophageal Canc... | Liposomal Irino... Carboplatin Capecitabine Oxaliplatin 5-fluorouracil Leucovorin | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM | NCT06021015 | Colorectal Canc... | Irinotecan and ... Irinotecan and ... | 18 Years - 80 Years | Zhongda Hospital | |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | NCT03577743 | Metastatic Trip... Safety Issues Efficacy | Bevacizumab | 18 Years - 75 Years | Assiut University | |
| A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma | NCT02773030 | Multiple Myelom... | CC-220 Dexamethasone Daratumumab Bortezomib Carfilzomib | 18 Years - | Celgene | |
| Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® | NCT05110170 | Breast Cancer | LY01005 ZOLADEX® 3.6 mg | 18 Years - 59 Years | Luye Pharma Group Ltd. | |
| De-escalation Study for Stage IIa/IIb < 3 cm Seminoma | NCT05529251 | Seminoma Stage II | Radiotherapy bo... Carboplatin AUC... 3 cycles of EP | 18 Years - | Centre Leon Berard | |
| Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma | NCT01736878 | Medullary Thyro... | Sorafenib | 18 Years - | Eanm Research Ltd | |
| Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer | NCT02575378 | Metastatic Colo... | Metronimic chem... Metronimic chem... | 18 Years - 75 Years | Ruijin Hospital | |
| Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | NCT04563936 | Prostate Cancer | LY01005 3.6 mg ZOLADEX® 3.6 mg | 50 Years - | Luye Pharma Group Ltd. | |
| Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma | NCT06141109 | Safety Issues Efficacy MTD | Sintilimab 200m... | 18 Years - 70 Years | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | |
| Bintrafusp Alfa Program Rollover Study | NCT05061823 | Lung Cancer Cancer | Bintrafusp alfa | 18 Years - | EMD Serono | |
| Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy | NCT00700440 | Nasopharyngeal ... | C225 (cetuximab... | 18 Years - 69 Years | Sun Yat-sen University | |
| Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma | NCT02908204 | Esophageal Neop... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | ||
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies | NCT01435447 | Lymphoid Malign... | FLu-Bu-Cy | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) | NCT00991744 | Acute Lymphobla... | Liposomal cytar... Intrathecal tri... | 1 Year - 18 Years | Nordic Society for Pediatric Hematology and Oncology | |
| Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases | NCT01799044 | Colorectal Live... Metastatic Live... | Irreversible el... | 18 Years - | Amsterdam UMC, location VUmc | |
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure | NCT01136499 | Soft Tissue Sar... | LBH589 (Panobin... | 18 Years - | Centre Leon Berard | |
| Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | NCT02411019 | Cervical Intrae... | GX-188E | 19 Years - 50 Years | Genexine, Inc. | |
| Use of Propranolol Hydrochloride in the Treatment of Metastatic STS | NCT03108300 | Malignant Soft ... | Propranolol Hyd... Doxorubicin | 19 Years - | Ain Shams University | |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | NCT03908138 | Hematologic Neo... Multiple Myelom... Efficacy Safety | RDD VDD | 18 Years - 65 Years | Shandong Provincial Hospital | |
| Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant | NCT00919399 | Breast Neoplasm... | Exemestane tamoxifen | 60 Years - | Institut Claudius Regaud | |
| Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma | NCT05540145 | Gastric Cancer | SOX plus Paclit... | 18 Years - 75 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor | NCT03590808 | Influenza Solid Carcinoma | Influenza vacci... | 20 Years - | Seoul National University Hospital | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments | NCT05443217 | Liver Cancer Microbiota Adverse Event Prognosis Efficacy | questionnaire s... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib | NCT01907607 | Advanced Gastro... | PD 0332991 | 18 Years - | Institut Bergonié | |
| Study of Apatinib as an Inhibitor of Tumor Angiogenesis | NCT00633490 | Tumor | apatinib | 18 Years - 70 Years | Fudan University | |
| Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer | NCT01861197 | Squamous NSCLC | Dovitinib | 20 Years - | Samsung Medical Center | |
| Efficacy of AFL-assisted PDT With Short Incubation Time in Actinic Keratosis | NCT02248298 | Actinic Keratos... | 2h-AFL-PDT 3h-AFL-PDT 3hr-MAL-PDT | 18 Years - 87 Years | Dong-A University | |
| Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01014208 | Lymphoma, Large... | OFATUMUMAB + DH... RITUXIMAB + DHA... | 18 Years - | GlaxoSmithKline | |
| Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer | NCT02091661 | Prostate Cancer | Radical retropu... External beam r... | - 75 Years | University of Rome Tor Vergata | |
| Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | NCT00824265 | Leukaemia, Lymp... | OFC Infusion FC infusion | 18 Years - | Novartis | |
| Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | NCT06302062 | Advanced Solid ... Tumor Associate... Immunotherapy | Tumor Associate... cyclophosphamid... IL-2 Serplulimab Inj... | 18 Years - 75 Years | Guangzhou FineImmune Biotechnology Co., LTD. | |
| Role of Propranolol as Compared to Bleomycin in Management of Hemangioma | NCT05327309 | Hemangioma Propranolol | Bleomycin | 6 Months - 12 Months | Shaheed Zulfiqar Ali Bhutto Medical University | |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | NCT03908138 | Hematologic Neo... Multiple Myelom... Efficacy Safety | RDD VDD | 18 Years - 65 Years | Shandong Provincial Hospital | |
| Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients | NCT05596890 | Esophageal Squa... Patient-reporte... Immunotherapy | Paclitaxel-albu... Cisplatin Carboplatin Tislelizumab VMAT or IMRT Esophagectomy | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) | NCT04907851 | Advanced Solid ... | RXC004 RXC004 RXC004 Denosumab pembrolizumab | 18 Years - | Redx Pharma Plc | |
| Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas | NCT04055220 | Bone Sarcoma Osteosarcoma Ewing Sarcoma Chondrosarcoma Undifferentiate... Leiomyosarcoma Angiosarcoma | Treatment by Re... Treatment by Pl... | 12 Years - | Centre Leon Berard | |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer | NCT01309126 | Colorectal Canc... | Imprime PGG + c... Cetuximab | 18 Years - | HiberCell, Inc. | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure | NCT01136499 | Soft Tissue Sar... | LBH589 (Panobin... | 18 Years - | Centre Leon Berard | |
| Efficacy and Safety Study of Complete Mesocolic Excision for Colon Cancer | NCT01724775 | Colon Cancer Surgery | 18 Years - | Peking University People's Hospital | ||
| Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy | NCT00700440 | Nasopharyngeal ... | C225 (cetuximab... | 18 Years - 69 Years | Sun Yat-sen University | |
| Apatinib in Advanced Non-squamous，NSCLC | NCT03376191 | Non-squamous No... | apatinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC | NCT01997957 | Hepatocellular ... | S-1 | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice | NCT02902900 | Multiple Myelom... | 18 Years - | Celgene | ||
| Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors | NCT01449357 | Non-small Cell ... | zalutumumab | 18 Years - | Genmab | |
| Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) | NCT01186640 | T-cell-prolymph... | Fludarabine, Mi... Alemtuzumab | 18 Years - | German CLL Study Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
